Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Experimental Clinical Trial

Official title:
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Status Not yet recruiting

Clinical Trial Summary

Study of Chidamide as a single-agent treatment for patients with relapse or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Clinical Trial Description

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Moreover, the aim was to study the correlation of clinical efficacy to mutation of certain genes as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03410004
Study type	Interventional
Source	Chinese Academy of Medical Sciences
Contact	Yuankai Shi, Dr.
Phone	010-67781331
Email	syuankai@cicams.ac.cn
Status	Not yet recruiting
Phase	Phase 2
Start date	January 25, 2018
Completion date	September 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03234790` - Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure	N/A
Completed	`NCT06197464` - FLOAT Through Anxiety: Virtual Reality Application's Efficacy as a Tool to Distract From Negative Emotions and Thoughts	N/A
Completed	`NCT03579706` - Evaluation of a Brief, Online Intervention for Military Personnel	N/A
Completed	`NCT03996785` - Effectiveness of Nature Walks in Depressed Adults	N/A
Recruiting	`NCT05344534` - Statewide System and Organizational Strategy for EBP Implementation	N/A
Recruiting	`NCT05024578` - Stimulating Brain Waves During Deep Sleep	N/A